Clinical Trials
8 trialsNCT05304377 2026-04-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT06787144 2025-07-01
CML
Enliven Therapeutics
Phase 1 Recruiting
NCT06530810 2024-07-31
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Not yet recruiting
NCT05367700 2023-01-13
A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03882281 2020-01-22
CML
Ascentage Pharma Group Inc.
Phase 1 Completed
NCT00324077 2016-02-17
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase
Bristol-Myers Squibb
Phase 1 Withdrawn
NCT00891137 2014-10-27
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy
Cellerant Therapeutics
Phase 1 Completed
NCT00103701 2011-04-14
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 1 Completed